We are a biopharmaceutical company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. We utilize a proprietary platform technology that facilitates the rapid high resolution measurement of immune cell function within small tissue biopsy samples. Our initial focus is on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors.
Company profile
Ticker
ENUM
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cerulean Group, Inc.
SEC CIK
Corporate docs
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
1 Jun 21
CT ORDER
Confidential treatment order
11 Jul 19
CT ORDER
Confidential treatment order
14 May 19
424B3
Prospectus supplement
29 Jan 18
8-K
Entry into a Material Definitive Agreement
29 Jan 18
424B3
Prospectus supplement
19 Dec 17
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Dec 17
10-Q
2017 Q3
Quarterly report
14 Nov 17
424B3
Prospectus supplement
14 Nov 17
424B3
Prospectus supplement
31 Oct 17
Latest ownership filings
SC 13G/A
Enumeral Biomedical Holdings, Inc.
13 Feb 18
SC 13G/A
Enumeral Biomedical Holdings, Inc.
12 Jan 18
SC 13D/A
Enumeral Biomedical Holdings, Inc.
15 Aug 17
SC 13D/A
Enumeral Biomedical Holdings, Inc.
1 Aug 17
SC 13G
Enumeral Biomedical Holdings, Inc.
10 Feb 17
SC 13G
Enumeral Biomedical Holdings, Inc.
23 Jan 17
4
NOSTRAND ROBERT L VAN
5 Jan 17
4
ROBERT J EASTON
5 Jan 17
4
ROBERT J EASTON
13 Dec 16
4
PAUL J SEKHRI
13 Dec 16
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|